Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
Summary Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
H Wang, Y Li, K Chai, Z Long, Z Yang, M Du, S Wang… - The Lancet - thelancet.com
Heart Failure | The Lancet Clinic Skip to Main Content Skip to Main Menu Advertisement The
Lancet Home Publish Log in Register Log in Publish Log in Subscribe Skip menu Main menu …
Lancet Home Publish Log in Register Log in Publish Log in Subscribe Skip menu Main menu …
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
J Butler, SJ Shah, MC Petrie, BA Borlaug… - 2024 - pubmed.ncbi.nlm.nih.gov
Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470)
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
[PDF][PDF] Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP …
J Butler, SJ Shah, MC Petrie, BA Borlaug… - 2024 - researchgate.net
Summary Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
J Butler, SJ Shah, MC Petrie… - The …, 2024 - researchinformation.amsterdamumc …
Background: In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470)
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
[引用][C] Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP …
J Butler, SJ Shah, MC Petrie, BA Borlaug… - ikm.ku.dk
Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470)
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
J Butler, SJ Shah, MC Petrie, BA Borlaug… - The Lancet, 2024 - Elsevier
Summary Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
(NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms …
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM …
J Butler, SJ Shah, MC Petrie, BA Borlaug… - Lancet (London …, 2024 - europepmc.org
Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470)
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …
trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations …